

Audit Review Table					
Blue Cross and Blue Shield of New Mexico, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company (Org ID: 1825, Sub ID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)					
Measurement Year - 2023; Date & Timestamp - 6/3/2024 10:39:41 AM					
This submission is on the stage: Finalize Attestation					
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment
Effectiveness of Care					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)					
<i>BMI percentile (Total)</i>		73.24%	R	R	Reported
<i>Counseling for Nutrition (Total)</i>		69.10%	R	R	Reported
<i>Counseling for Physical Activity (Total)</i>		64.96%	R	R	Reported
Childhood Immunization Status (CIS)					
<i>DTaP</i>		72.51%	R	R	Reported
<i>IPV</i>		86.86%	R	R	Reported
<i>MMR</i>		83.70%	R	R	Reported
<i>HiB</i>		85.40%	R	R	Reported
<i>Hepatitis B</i>		88.56%	R	R	Reported
<i>VZV</i>		82.24%	R	R	Reported
<i>Pneumococcal Conjugate</i>		72.75%	R	R	Reported
<i>Hepatitis A</i>		82.48%	R	R	Reported
<i>Rotavirus</i>		71.78%	R	R	Reported
<i>Influenza</i>		38.69%	R	R	Reported
<i>Combo 3</i>		64.72%	R	R	Reported
<i>Combo 7</i>		56.45%	R	R	Reported
<i>Combo 10</i>		30.17%	R	R	Reported
Immunizations for Adolescents (IMA)					
<i>Meningococcal</i>		81.58%	R	R	Reported
<i>Tdap</i>		82.75%	R	R	Reported
<i>HPV</i>		32.74%	R	R	Reported
<i>Combination 1</i>		80.66%	R	R	Reported
<i>Combination 2</i>		32.07%	R	R	Reported
Lead Screening in Children (LSC)					
<i>Lead Screening in Children</i>		37.86%	R	R	Reported
Cervical Cancer Screening (CCS)					
<i>Cervical Cancer Screening</i>		53.28%	R	R	Reported
Colorectal Cancer Screening (COL)					
<i>(Total)</i>		32.87%	R	R	Reported
Chlamydia Screening in Women (CHL)					
<i>(Total)</i>		48.10%	R	R	Reported
Oral Evaluation, Dental Services (OED)					
	Y				
<i>(0-2)</i>		26.57%	R	R	Reported
<i>(3-5)</i>		58.05%	R	R	Reported
<i>(6-14)</i>		59.89%	R	R	Reported
<i>(15-20)</i>		41.09%	R	R	Reported
<i>(Total)</i>		50.69%	R	R	Reported
Topical Fluoride for Children (TFC)					
<i>(1-2)</i>		8.15%	R	R	Reported
<i>(3-4)</i>		9.36%	R	R	Reported
<i>(Total)</i>		8.76%	R	R	Reported
Appropriate Testing for Pharyngitis (CWP)					
	Y				
<i>(Total)</i>		75.44%	R	R	Reported
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)					
<i>Use of Spirometry Testing in the Assessment and Diagnosis of COPD</i>		22.48%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation (PCE)					
	Y				
<i>Systemic Corticosteroid</i>		56.00%	R	R	Reported
<i>Bronchodilator</i>		63.79%	R	R	Reported
Asthma Medication Ratio (AMR)					
	Y				
<i>(Total)</i>		83.41%	R	R	Reported
Controlling High Blood Pressure (CBP)					
<i>Controlling High Blood Pressure</i>		54.01%	R	R	Reported
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)					
	Y				
<i>Persistence of Beta-Blocker Treatment After a Heart Attack</i>		44.26%	R	R	Reported
Statin Therapy for Patients With Cardiovascular Disease (SPC)					
	Y				
<i>Received Statin Therapy (Total)</i>		64.97%	R	R	Reported
<i>Statin Adherence 80% (Total)</i>		68.15%	R	R	Reported
Cardiac Rehabilitation (CRE)					
<i>Initiation (Total)</i>		4.49%	R	R	Reported

Engagement1 (Total)		7.39%	R	R	Reported
Engagement2 (Total)		6.33%	R	R	Reported
Achievement (Total)		2.64%	R	R	Reported
Hemoglobin A1c Control for Patients With Diabetes (HBD)					
HbA1c Control (<8%)		40.15%	R	R	Reported
Poor HbA1c Control		51.09%	R	R	Reported
Blood Pressure Control for Patients With Diabetes (BPD)					
Blood Pressure Control for Patients With Diabetes		53.53%	R	R	Reported
Eye Exam for Patients With Diabetes (EED)					
Eye Exam for Patients With Diabetes		41.12%	R	R	Reported
Kidney Health Evaluation for Patients With Diabetes (KED)					
(Total)		31.85%	R	R	Reported
Statin Therapy for Patients With Diabetes (SPD)	Y				
Received Statin Therapy		51.52%	R	R	Reported
Statin Adherence 80%		63.63%	R	R	Reported
Diagnosed Mental Health Disorders (DMH)					
(Total)		30.48%	R	R	Reported
Antidepressant Medication Management (AMM)	Y				
Effective Acute Phase Treatment		59.73%	R	R	Reported
Effective Continuation Phase Treatment		42.52%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	Y				
Initiation Phase		46.02%	R	R	Reported
Continuation and Maintenance Phase		57.92%	R	R	Reported
Follow-Up After Hospitalization for Mental Illness (FUH)	Y				
30 days (Total)		55.07%	R	R	Reported
7 days (Total)		34.16%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Y				
30 days (Total)		58.28%	R	R	Reported
7 days (Total)		45.13%	R	R	Reported
Diagnosed Substance Use Disorders (DSU)					
Alcohol (Total)		4.55%	R	R	Reported
Opioid (Total)		4.31%	R	R	Reported
Other (Total)		5.27%	R	R	Reported
Any (Total)		10.61%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)	Y				
30 days (Total)		48.75%	R	R	Reported
7 Days (Total)		26.27%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use (FUA)	Y				
30 days (Total)		37.13%	R	R	Reported
7 days (Total)		24.02%	R	R	Reported
Pharmacotherapy for Opioid Use Disorder (POD)	Y				
(Total)		13.27%	R	R	Reported
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	Y				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications		80.55%	R	R	Reported
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)					
Diabetes Monitoring for People With Diabetes and Schizophrenia		58.82%	R	R	Reported
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)					
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia		63.16%	NA	R	Reported
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y				
Adherence to Antipsychotic Medications for Individuals With Schizophrenia		54.37%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	Y				
Blood Glucose Testing (Total)		58.32%	R	R	Reported
Cholesterol Testing (Total)		34.26%	R	R	Reported
Blood Glucose and Cholesterol Testing (Total)		32.81%	R	R	Reported
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)					
Non-Recommended Cervical Cancer Screening in Adolescent Females		0.58%	R	R	Reported
Appropriate Treatment for Upper Respiratory Infection (URI)	Y				
(Total)		81.18%	R	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	Y				
(Total)		55.61%	R	R	Reported

Use of Imaging Studies for Low Back Pain (LBP)					
<i>(Total)</i>		68.32%	R	R	Reported
Use of Opioids at High Dosage (HDO)	Y				
<i>Use of Opioids at High Dosage</i>		3.08%	R	R	Reported
Use of Opioids From Multiple Providers (UOP)	Y				
<i>Multiple Prescribers</i>		14.71%	R	R	Reported
<i>Multiple Pharmacies</i>		1.98%	R	R	Reported
<i>Multiple Prescribers and Multiple Pharmacies</i>		1.24%	R	R	Reported
Risk of Continued Opioid Use (COU)	Y				
<i>>=15 Days (Total)</i>		4.78%	R	R	Reported
<i>>=31 Days (Total)</i>		3.46%	R	R	Reported
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (AAP)					
<i>(Total)</i>		72.03%	R	R	Reported
Initiation and Engagement of Substance Use Disorder Treatment (IET)	Y				
<i>Initiation of SUD Treatment - Total (Total)</i>		45.93%	R	R	Reported
<i>Engagement of SUD Treatment - Total (Total)</i>		15.80%	R	R	Reported
Prenatal and Postpartum Care (PPC)					
<i>Timeliness of Prenatal Care</i>		85.16%	R	R	Reported
<i>Postpartum Care</i>		72.26%	R	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Y				
<i>(Total)</i>		59.87%	R	R	Reported
Utilization and Risk Adjusted Utilization					
Well-Child Visits in the First 30 Months of Life (W30)					
<i>(First 15 Months)</i>		64.34%	R	R	Reported
<i>(15 Months-30 Months)</i>		66.46%	R	R	Reported
Child and Adolescent Well-Care Visits (WCV)					
<i>(Total)</i>		46.94%	R	R	Reported
Ambulatory Care (AMB)			R	R	Reported
Inpatient Utilization - General Hospital/Acute Care (IPU)			R	R	Reported
Antibiotic Utilization for Respiratory Conditions (AXR)	Y				
<i>(Total)</i>		29.51%	R	R	Reported
Plan All-Cause Readmissions (PCR)			R	R	Reported
Health Plan Descriptive Information					
Enrollment by Product Line (ENP)			R	R	Reported
Language Diversity of Membership (LDM)			R	R	Reported
Race/Ethnicity Diversity of Membership (RDM)			R	R	Reported
Measures Reported Using Electronic Clinical Data Systems					
Childhood Immunization Status (CIS-E)					
<i>DTaP</i>		70.76%	R	R	Reported
<i>IPV</i>		85.22%	R	R	Reported
<i>MMR</i>		85.54%	R	R	Reported
<i>HiB</i>		83.83%	R	R	Reported
<i>Hepatitis B</i>		85.45%	R	R	Reported
<i>VZV</i>		85.05%	R	R	Reported
<i>Pneumococcal Conjugate</i>		71.58%	R	R	Reported
<i>Hepatitis A</i>		84.36%	R	R	Reported
<i>Rotavirus</i>		70.17%	R	R	Reported
<i>Influenza</i>		37.42%	R	R	Reported
<i>Combo 3</i>		63.19%	R	R	Reported
<i>Combo 7</i>		55.66%	R	R	Reported
<i>Combo 10</i>		28.53%	R	R	Reported
Immunizations for Adolescents (IMA-E)					
<i>Meningococcal</i>		81.58%	R	R	Reported
<i>Tdap</i>		82.75%	R	R	Reported
<i>HPV</i>		32.74%	R	R	Reported
<i>Combination 1</i>		80.66%	R	R	Reported
<i>Combination 2</i>		32.07%	R	R	Reported
Breast Cancer Screening (BCS-E)					
<i>Breast Cancer Screening</i>		45.63%	R	R	Reported
Cervical Cancer Screening (CCS-E)					
<i>Cervical Cancer Screening</i>		46.20%	R	R	Reported
Colorectal Cancer Screening (COL-E)					
<i>(Total)</i>			NR	NR	Not Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)	Y				
<i>Initiation Phase</i>		46.02%	R	R	Reported
<i>Continuation and Maintenance Phase</i>		57.73%	R	R	Reported

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)	Y				
<i>Blood Glucose Testing (Total)</i>		58.08%	R	R	Reported
<i>Cholesterol Testing (Total)</i>		34.14%	R	R	Reported
<i>Blood Glucose and Cholesterol Testing (Total)</i>		32.69%	R	R	Reported
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)					
<i>Depression Screening (Total)</i>		0.00%	R	R	Reported
<i>Follow-Up on Positive Screen (Total)</i>			NA	R	Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)					
<i>Utilization of PHQ-9-Total (Total)</i>		0.00%	R	R	Reported
Depression Remission or Response for Adolescents and Adults (DRR-E)					
<i>Follow-Up PHQ-9 (Total)</i>			NA	R	Reported
<i>Depression Remission (Total)</i>			NA	R	Reported
<i>Depression Response (Total)</i>			NA	R	Reported
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)					
<i>Unhealthy Alcohol Use Screening (Total)</i>		0.00%	R	R	Reported
<i>Alcohol Counseling or Other Follow-Up Care (Total)</i>			NA	R	Reported
Adult Immunization Status (AIS-E)					
<i>Influenza (19-65)</i>		18.51%	R	R	Reported
<i>Influenza (66+)</i>		45.07%	R	R	Reported
<i>Influenza (Total)</i>		19.39%	R	R	Reported
<i>Td/Tdap (19-65)</i>		36.95%	R	R	Reported
<i>Td/Tdap (66+)</i>		30.04%	R	R	Reported
<i>Td/Tdap (Total)</i>		36.72%	R	R	Reported
<i>Zoster (50-65)</i>		11.86%	R	R	Reported
<i>Zoster (66+)</i>		17.50%	R	R	Reported
<i>Zoster (Total)</i>		12.55%	R	R	Reported
<i>Pneumococcal (66+)</i>		50.60%	R	R	Reported
Prenatal Immunization Status (PRS-E)					
<i>Influenza</i>		33.49%	R	R	Reported
<i>Tdap</i>		60.89%	R	R	Reported
<i>Combination</i>		28.68%	R	R	Reported
Prenatal Depression Screening and Follow-Up (PND-E)					
<i>Depression Screening</i>		0.00%	R	R	Reported
<i>Follow-Up on Positive Screen</i>			NA	R	Reported
Postpartum Depression Screening and Follow-Up (PDS-E)					
<i>Depression Screening</i>		0.00%	R	R	Reported
<i>Follow-Up on Positive Screen</i>			NA	R	Reported
Social Need Screening and Intervention (SNS-E)					
<i>Food Screening (Total)</i>		0.00%	R	R	Reported
<i>Food Intervention (Total)</i>			NA	R	Reported
<i>Housing Screening (Total)</i>		0.00%	R	R	Reported
<i>Housing Intervention (Total)</i>			NA	R	Reported
<i>Transportation Screening (Total)</i>		0.00%	R	R	Reported
<i>Transportation Intervention (Total)</i>			NA	R	Reported